Hepatic Safety of Statin Use in Neurology Inpatients
ConditionStatin Adverse Reaction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorShanghai Yueyang Integrated Medicine Hospital
About this trial
This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.
Eligibility criteria
Qualifiers
Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.
Age ≥18 and ≤85 years old, both sexes.
Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.
Disqualifiers
Incomplete medical history.
1 days ≤ patients with < 7 days of prior statin use.
Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).
Trial design
Treatments tested in this trial
- stain
Treatment groups
2,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov